Antibody response to the pneumococcal proteins pneumococcal surface adhesin A and pneumolysin in children with acute otitis media

Background. Pneumococcal surface adhesin A (PsaA) and pneumolysin (Ply) are common to virtually all Streptococcus pneumoniae isolates, and they are immunogenic and protective against pneumococcal challenge in experimental animals. We have recently shown production of antibodies to PsaA and Ply in young children, but data on the immune response to these antigens during culture-confirmed pneumococcal infection are lacking. Objectives. To evaluate whether young children respond to S. pneumoniae by producing antibodies to PsaA and Ply during acute otitis media (AOM). Subjects and methods. A cohort of 329 children was followed prospectively from the age of 2 months to the age of 2 years. Paired sera were obtained during episodes of AOM and used to measure antibodies to PsaA and Ply by enzyme-linked immunosorbent assay. S. pneumoniae cultured from the middle ear fluid was taken as evidence of pneumococcal AOM. The presence of S. pneumoniae in the nasopharyngeal aspirate collected in connection of AOM or any other respiratory infection or in the nasopharyngeal swab collected at scheduled visits was taken to indicate pneumococcal carriage and thus a history of previous contact with S. pneumoniae. Results. Children with previous pneumococcal contacts had high anti-PsaA and anti-Ply concentrations in the acute phase sera regardless of the nature (AOM or carriage) of the current pneumococcal contact. Of the children with no previous pneumococcal contact, those with current pneumococcal AOM had lower antibody concentrations than those with current pneumococcal carriage only. Anti-PsaA and anti-Ply responses were found in children with current pneumococcal contact. The antibody response was strongly associated with low acute phase antibody concentration, but not significantly with age and the nature of the current pneumococcal contact. Conclusions. We showed that infants are capable of developing a specific antibody response to the pneumococcal proteins PsaA and Ply during AOM.

[1]  S. Lockhart,et al.  Efficacy of a pneumococcal conjugate vaccine against acute otitis media. , 2001, The New England journal of medicine.

[2]  G. Carlone,et al.  Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media. , 2000, The Journal of infectious diseases.

[3]  E. Lewis,et al.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children , 2000, The Pediatric infectious disease journal.

[4]  N. Yamanaka,et al.  Immune Responses to Specific Antigens of Streptococcus pneumoniae and Moraxella catarrhalis in the Respiratory Tract , 2000, Infection and Immunity.

[5]  D. Briles,et al.  Human antibodies to pneumococcal surface protein A in health and disease , 2000, The Pediatric infectious disease journal.

[6]  R. Huebner,et al.  Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. , 1999, The Journal of infectious diseases.

[7]  P. Andrew,et al.  Biological properties of pneumolysin. , 1997, Microbial drug resistance.

[8]  D. Talkington,et al.  Protection of mice against fatal pneumococcal challenge by immunization with pneumococcal surface adhesin A (PsaA). , 1996, Microbial pathogenesis.

[9]  M. Leinonen,et al.  Comparison of serum antibodies to pneumolysin with those to pneumococcal capsular polysaccharides in children with acute otitis media. , 1996, The Pediatric infectious disease journal.

[10]  L. McDaniel,et al.  Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. , 1996, The Journal of infectious diseases.

[11]  P. Andrew,et al.  Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae , 1994, Infection and immunity.

[12]  Pneumococcal conjugate vaccines. , 2012, Immunology letters.

[13]  L. McDaniel,et al.  PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type , 1991, Infection and immunity.

[14]  P. Mäkelä,et al.  A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. , 1990, The New England journal of medicine.

[15]  P. Mäkelä,et al.  Immunogenicity of Haemophilus influenzae oligosaccharide-protein and polysaccharide-protein conjugate vaccination of children at 4, 6, and 14 months of age. , 1989, Pediatrics.